Prediction of low versus high recurrence scores in estrogen receptor-Positive, lymph node-negative invasive Breast cancer on the Basis of radiologic-Pathologic Features: Comparison with Oncotype DX Test Recurrence Scores1

Radiology

Volumn 280, Issue 2, 2016, Pages 370-378

  Dialani, Vandana ^a   Gaur, Shantanu ^b   Mehta, Tejas S ^a   Venkataraman, Shambhavi ^a   Fein Zachary, Valerie ^a   Phillips, Jordana ^a   Brook, Alexander ^a   Slanetz, Priscilla J ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; PROGESTERONE RECEPTOR; ESTROGEN RECEPTOR;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER GRADING; CANCER RECURRENCE; CANCER TEST; CONTROLLED STUDY; ECHOGRAPHY; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; GENOMICS; HISTOPATHOLOGY; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MAMMOGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOTYPE DX; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SINGLE BLIND PROCEDURE; BREAST NEOPLASMS; COMPARATIVE STUDY; DIAGNOSTIC IMAGING; GENE EXPRESSION PROFILING; GENETICS; LYMPH NODE; MIDDLE AGED; PROCEDURES; REPRODUCIBILITY; STATISTICS AND NUMERICAL DATA; TUMOR RECURRENCE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; LYMPH NODES; MAMMOGRAPHY; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RECEPTORS, ESTROGEN; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES;

EID: 84979887684     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.2016151149     Document Type: Article

References (21)

1. Boyages J, Taylor R, Chua B, et al. A risk index for early node-negative breast cancer. Br J Surg 2006;93(5):564-571.
2. Asad J, Jacobson AF, Estabrook A, et al. Does oncotype DX recurrence score affect the management of patients with early-stage breast cancer? Am J Surg 2008;196(4):527-529.
3. Sparano JA, Paik S. Development of the 21-gene assay and its application in clinical practice and clinical trials. J Clin Oncol 2008;26(5):721-728.
4. Carlson RW, Allred DC, Anderson BO, et al. Breast cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw 2009;7(2):122-192.
5. Dinan MA, Mi X, Reed SD, Hirsch BR, Ly-man GH, Curtis LH. Initial trends in the use of the 21-gene recurrence score assay for patients with breast cancer in the Medicare population, 2005-2009. JAMA Oncol 2015;1(2):158-166.
6. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351(27):2817-2826.
7. Ingoldsby H, Webber M, Wall D, Scarrott C, Newell J, Callagy G. Prediction of Onco-type DX and TAILORx risk categories using histopathological and immunohistochemical markers by classifcation and regression tree (CART) analysis. Breast 2013;22(5):879-886.
8. Cuzick J, Dowsett M, Pineda S, et al. Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer. J Clin Oncol 2011;29(32):4273-4278.
9. Pereira H, Pinder SE, Sibbering DM, et al. Pathological prognostic factors in breast cancer. IV: Should you be a typer or a grader? A comparative study of two histological prognostic features in operable breast carcinoma. Histopathology 1995;27(3):219-226.
10. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of his-tological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 2002;41(3A):154-161.
11. Pinder SE, Ellis IO, Elston CW. Prognostic factors in primary breast carcinoma. J Clin Pathol 1995;48(11):981-983.
12. Chen C, Yuan JP, Wei W, et al. Subtype classifcation for prediction of prognosis of breast cancer from a biomarker panel: correlations and indications. Int J Nanomedi-cine 2014;9:1039-1048.
13. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of his-tological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991;19(5):403-410.
14. Pinder SE, Wencyk P, Sibbering DM, et al. Assessment of the new proliferation marker MIB1 in breast carcinoma using image analysis: associations with other prognostic factors and survival. Br J Cancer 1995;71(1):146-149.
15. Klein ME, Dabbs DJ, Shuai Y, et al. Prediction of the Oncotype DX recurrence score: use of pathology-generated equations derived by linear regression analysis. Mod Pathol 2013;26(5):658-664.
16. Lee JJ, Shen J. Is the Oncotype DX assay necessary in strongly estrogen receptor-positive breast cancers? Am Surg 2011;77(10):1364-1367.
17. Tang P, Wang J, Hicks DG, et al. A lower Allred score for progesterone receptor is strongly associated with a higher recurrence score of 21-gene assay in breast cancer. Cancer Invest 2010;28(9):978-982.
18. Magennis DP. Angiogenesis: a new prognostic marker for breast cancer. Br J Biomed Sci 1998;55(3):214-220.
19. Jiang J, Chen YQ, Xu YZ, et al. Correlation between three-dimensional ultrasound features and pathological prognostic factors in breast cancer. Eur Radiol 2014;24(6):1186-1196.
20. Shin HJ, Kim HH, Huh MO, et al. Correlation between mammographic and sono-graphic fndings and prognostic factors in patients with node-negative invasive breast cancer. Br J Radiol 2011;84(997):19-30.
21. Evans AJ, Pinder SE, James JJ, Ellis IO, Corn-ford E. Is mammographic spiculation an independent, good prognostic factor in screening-detected invasive breast cancer? AJR Am J Roentgenol 2006;187(5):1377-1380.